FDA Approves TOPIRAMATE — Teva Pharmaceuticals, Inc.
Teva Pharmaceuticals announced on March 10, 2023, the FDA approval of its generic version of FDA-approved with its High Blood Pressure drugs (HBP) and epilepsy. This approval allows Teva to enter a lucrative market, further strengthening its generics portfolio amidst ongoing industry competitiveness.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed